The Schizophrenia Market is segmented by route of administration, with oral antipsychotics holding the largest share. According to the MRFR report, the oral route is preferred due to its ease of use, convenience, and patient compliance. Oral medications allow for straightforward self-administration at home, aligning with patient preferences. The oral segment was valued at USD 4.97 billion in 2024 and is projected to remain the dominant route throughout the forecast period.

While oral administration leads, injectable formulations are the fastest-growing segment. Long-acting injectable (LAI) antipsychotics are gaining traction due to their innovative formulations that enhance adherence and minimize the risk of relapse. LAI formulations offer extended intervals between doses, ranging from two weeks to six months, addressing a critical challenge in schizophrenia management—medication non-adherence. The approval of Paliperidone Palmitate 6-Month (PP6M) by the FDA would make it the only long-acting injectable schizophrenia medication with a twice-yearly dosing regimen. The injectables segment was valued at USD 3.32 billion in 2024 and is projected to grow significantly.

The growth of the injectables segment is driven by the recognition that treatment adherence is a major determinant of outcomes in schizophrenia. Poor adherence leads to relapse, hospitalization, and functional decline. LAIs provide a solution by ensuring consistent medication delivery, reducing the burden on patients and caregivers. As healthcare providers recognize the importance of adherence, the injectables segment is positioned for accelerated growth, catering to a specific patient demographic that may struggle with oral medication compliance.

The development of new LAI formulations with improved tolerability and longer dosing intervals is a key area of research. Companies are also exploring novel delivery technologies, such as subcutaneous implants and microsphere formulations, that could further extend dosing intervals. The increasing availability of LAIs, combined with patient education and support programs, is expected to drive adoption.

The shift towards injectable formulations also reflects a broader trend towards personalized medicine. The choice between oral and injectable administration depends on patient preference, clinical history, and the phase of illness. For patients in the acute phase or those with a history of poor adherence, LAIs may be preferred. For stable patients, oral medications may be sufficient. The availability of multiple administration routes allows clinicians to tailor treatment to individual patient needs, improving outcomes and quality of life.